Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 2, 2018

Primary Completion Date

August 7, 2020

Study Completion Date

August 7, 2020

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX/TEZ/IVA

Fixed-dose combination tablet orally once daily in the morning.

DRUG

IVA

IVA tablet orally once daily in the evening.

Trial Locations (21)

11040

Northwell Health- Long Island Jewish Medical Center, New Hyde Park

28277

Clinical Research of Charlotte, Charlotte

43205

Nationwide Children's Hospital, Columbus

44106

Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland

55404

Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota, Minneapolis

60611

Ann & Robert Lurie Children's Hospital of Chicago, Chicago

64108

The Children's Mercy Hospital, Kansas City

77030

Texas Children's Hospital, Houston

80045

Children's Hospital Colorado, Aurora

92868

Children's Hospital of Orange County, Orange

97239

Oregon Health & Science University, Portland

98105

Seattle Children's Hospital, Seattle

02115

Boston Children's Hospital, Boston

Unknown

Queensland Children's Hospital, South Brisbane

The Children's Hospital at Westmead, Westmead

The Hospital for Sick Children, Toronto

British Columbia's Children's Hospital, Vancouver

Children's Health Ireland at Crumlin, Dublin

Children's Health Ireland at Temple Street, Dublin

Birmingham Children's Hospital, Birmingham

Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital, London

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03691779 - Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age | Biotech Hunter | Biotech Hunter